Study CERE-110-03 is a Phase 2 clinical trial of CERE-110 in patients with mild to moderate Alzheimer's disease. This study is being conducted in collaboration with the Alzheimer's Disease Cooperative Study (ADCS).
This study will evaluate whether Ceregene's CERE-110 (AAV_NGF) is a safe and effective treatment for Alzheimer's Disease (AD). The study is being conducted at 11 sites throughout the United States.
Approximately fifty people with AD participated in this study. Half of the study subjects will undergo brain surgery to receive CERE-110, while the other half will undergo a similar surgery without receiving CERE-110 ("sham" or "mock" surgery).
Participants are carefully monitored by a team of study doctors and nurses for three years after the study surgery. There is no charge to participate in this study. [MORE INFO]
The purpose of this Phase 2b study is to evaluate the safety and potential benefits of CERE-120 for Parkinson's disease. CERE-120 is an experimental drug that has been safely tested in over 60 people with Parkinson's disease. It employs a vector to transfer the gene that makes neurturin directly into brain cells most affected by Parkinson's disease. Neurturin is a neurotrophic factor shown in laboratory experiments to restore damaged dopamine cells and protect them from further degeneration.
Approximately fifty two people with PD will participate in this study. Once enrolled, half will undergo surgery to receive CERE-120 and the other half will undergo a placebo surgery where no medication will be injected. Participants in the study will be carefully followed by a team of experts, at no cost. [MORE INFO]